Promoting BVN Ablation Coverage

On May 1, 2025, IPSIS submitted a letter 🔒 to UnitedHealthcare (UHC) urging a policy change to align with both science and patient needs. Despite strong clinical evidence, commercial and Medicare coverage, UHC continues to classify intraosseous basivertebral nerve (BVN) ablation as "experimental." The letter emphasized the level of safety, specificity, and long-term benefit seen with BVN ablation.

IPSIS called on UHC to revise its outdated policy and recognize BVN ablation as a life-improving, cost-saving treatment.

Experiencing coverage issues? Want to make a difference? Contact advocacy@IPSISmed.org to take action.

You can also help sustain this vital advocacy with your donations. The International Pain and Spine Intervention Society (IPSIS) is a tax exempt organization under US section 501(c)(3) of the Internal Revenue Code. As such, contributions are deductible to the extent allowed by law.